1. This company is the leader of antibiotics and the largest production base of antibiotic medicine products in China. The total output of antibiotic raw materials accounts for about 15% of the total national output, and the annual production capacity of powder injection reaches 2.2 billion, ranking first in the country. Among them, the output of penicillin and vitamin B 12 ranks first in Asia and second in the world. The output of semi-synthetic penicillin and its intermediates ranks first in Asia; Streptomycin production ranks first in the world; The products of kasugamycin rank first in Asia; The output of abamectin refined powder ranks first in Asia; The output of powder injection ranks first in Asia.
2. The company and its subsidiary, Xiantai Company, obtained the national high-tech enterprise certification qualification certificate. According to relevant regulations, it has enjoyed the preferential income tax rate of 15% for three consecutive years since 2008.
3. The company's new cephalosporin series project will be built in Shijiazhuang Economic Development Zone, which is divided into two parts: preparation and raw materials. The planned area is 300 mu, and the project investment is expected to be 6 billion.